Compulsory licensing and access to drugs
Tóm tắt
Compulsory licensing allows the use of a patented invention without the owner’s consent, with the aim of improving access to essential drugs. The pharmaceutical sector argues that, if broadly used, it can be detrimental to innovation. We model the interaction between a company in the North that holds the patent for a certain drug and a government in the South that needs to purchase it. We show that both access to drugs and pharmaceutical innovation depend largely on the Southern country’s ability to manufacture a generic version. If the manufacturing cost is too high, compulsory licensing is not exercised. As the cost decreases, it becomes a credible threat forcing prices down, but reducing both access and innovation. When the cost is low enough, the South produces its own generic version and access reaches its highest value, despite a reduction in innovation. The global welfare analysis shows that the overall impact of compulsory licensing can be positive, even when accounting for its impact on innovation. We also consider the interaction between compulsory licensing and the strength of intellectual property rights, which can have global repercussions in other markets beyond the South.
Tài liệu tham khảo
Bale, H.E.: The conflicts between parallel trade and product access and innovation: the case of pharmaceuticals. J. Int. Econ. Law 1(4), 637–653 (1998)
Bardey, D., Bommier, A., Jullien, B.: Retail price regulation and innovation: Reference pricing in the pharmaceutical industry. J. Health Econ. 29(2), 303–316 (2010)
Bennato, A.R., Valletti, T.: Pharmaceutical innovation and parallel trade. CEPR Discussion Paper (2011)
Brekke, K., Königbauerb, I., Straume, O.R.: Reference pricing of pharmaceuticals. J. Health Econ. 26(3), 613–642 (2007)
Chaudhuri, S., Goldberg, P., Jia, P.: Estimating the effects of global patent protection in pharmaceuticals: a case study of quinolones in India. Am. Econ. Rev. 96, 1477–1514 (2006)
Coco, R., Nebbia, P.: Compulsory licensing and interim measures in Merck: a case for Italy or for antitrust? J. Intellect. Prop. Law Pract. 2(7), 452–462 (2007)
Cohen, J.: Expanding drug access in Brazil: lessons for Latin America and Canada. Can. J. Public Health 97(6), 15–18 (2006)
Cohen, J.: Brazil, Thailand override big pharma patents. Science 11, 816 (2007)
Danzon, P.M.: Price discrimination for pharmaceuticals: welfare effects in the US and the EU. Int. J. Econ. Bus. 4(3), 301–321 (1997)
Danzon, P.M., Towse, A.: Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int. J. Health Care Finance Econ. 3, 183–205 (2003)
Danzon, P.M., Wang, R., Wang, L.: The impact of price regulation on the launch delay of new drugs—evidence from twenty-five major markets in the 1990s. Health Econ. 14(3), 269–292 (2005)
Galizzi, M., Ghislandi, S., Miraldo, M.: Effects of reference pricing in pharmaceutical markets: a review. PharmacoEconomics 29(1), 17–33 (2011)
Ganslandt, M., Maskus, K.E.: Parallel imports and the pricing of pharmaceutical products: evidence from the EU. J. Health Econ. 23, 1035–1057 (2004)
Garcia Mariñoso, B., Jelovac, I., Olivella, P.: External referencing and pharmaceutical price negotiation. Health Econ. 20(6), 737–756 (2011)
Goroff, M., Reich, M.: Partnership to provide care and medicine for chronic diseases: a model for emerging markets. Health Affairs 29(12), 2206–2213 (2010)
Grossman, G.M., Lai, E.: Parallel imports and price control. RAND J. Econ. 39(2), 378–402 (2008)
Guo, S., Hu, B., Zhong, H.: Impact of parallel trade on pharmaceutical firm’s profits: rise or fall? Eur. J. Health Econ. 14(2), 345–355 (2013)
Hornbeck, R.: Price discrimination and smuggling of AIDS drugs. Top. Econ. Anal. Policy 5(1), article 16 (2005)
Jelovac, I., Bordoy, C.: Pricing and welfare implications of parallel imports in the pharmaceutical industry. Int. J. Health Care Finance Econ. 5, 5–21 (2005)
Kerr, A.W., Gaisford, J.D.: Handbook on International Trade Policy. Edward Elgar Publishing Limited, UK (2007)
Lybecker, K.M., Fowler, E.: Compulsory licensing in Canada and Thailand: comparing regimens to ensure legitimate use of the WTO rules. J. Law Med. Ethics 37(2), 222–239 (2009)
Mantovani, A., Naghavi, A.: Parallel imports and innovation in an emerging economy: the case of Indian pharmaceuticals. Health Econ. 21(11), 1286–1299 (2012)
Maskus, K.E.: Intellectual property rights in the global economy. Institute for International Economics, Washington, DC (2000)
Matthews, D.: WTO Decision on Implementation of paragraph 6 of the DOHA Declaration on the TRIPs agreement and Public Health: a solution to the access to essential medicines problem? J. Int. Econ. Law 7(1), 73–107 (2004)
Miraldo, M.: Reference pricing and firms’ pricing strategies. J. Health Econ. 28(1), 176–197 (2009)
Morais, R.: Parallel imports and price controls. Mimeo (2005)
Mussa, M., Rosen, S.: Monopoly and product quality. J. Econ. Theory 18(2), 301–317 (1978)
NHSO (2007) Facts and evidences on the 10 burning issues related to the government use of patents on three patented drugs in Thailand. The Ministry of Public Health and The National Health Security Office Thailand, National Health and Security Office
Pecorino, P.: Should the US allow prescription drug reimports from Canada? J. Health Econ. 21, 699–708 (2002)
Pécoul, B., Chirac, P., Trouiller, P.: Access to essential drugs in poor countries—a lost battle? J. Am. Med. Assoc. 281, 361–367 (1999)
Reichman, J.: The aims of health policy are often in conflict with those of economic trade. J. Law Med. Ethics 37(2), 247–263 (2009)
Rozek, R.P.: The effects of compulsory licensing on innovation and access to health care. J. World Intellect. Prop. 3(6), 889–917 (2000)
Scherer, F.M., Watal, J.: Post-TRIPS options for access to patented medicines in developing nations. J. Int. Econ. Law 5(4), 913–939 (2002)
Steinbrook, R.: Thailand and the compulsory licensing of efavirenz. N. Engl. J. Med. 6, 544–546 (2007)
Valletti, T., Szymanski, S.: Parallel trade, international exhaustion and IPRs: a welfare analysis. J. Ind. Econ. 54(4), 499–526 (2006)
van Zimmeren, E., Requena, G.: Ex-officio licensing in the medical sector: the French model. In: Van Overwalle, G. (ed.) Gene Patents and Public Health, Bruylant, Brussels (2007)
WHO (2002) Medicines strategy 2000–2003: framework for action in essential drugs and medicines policy, World Health Organization, Geneva
Wright, D.: The drug bargaining game: pharmaceutical regulation in Australia. J. Health Econ. 23, 785–813 (2004)